Citations

Clear

6273 citation(s) found for "To, Andrew".

Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data
Gunderson, Leonard L., Jessup, J. Milburn , Sargent, Daniel J. , Greene, Frederick L. , Stewart, Andrew K., Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | November 30, 2009 | Volume: 28 | Issue: 2 | Pages: 264-271

10.1200/jco.2009.24.0952 | PMID 19949014 Get It

Purpose The sixth edition of American Joint Committee on Cancer (AJCC) Cancer Staging Manual for colon cancer subdivided stage II into IIA (T3N0) and IIB (T4N0) and stage III into IIIA (T1-2N1M0), IIIB (T3-4N1M0), and IIIC (anyTN2M0). Subsequent analyses supported revised substaging of stage III because of improved survival for T1-2N2 versus T3-4N2 and T4N1 survival was more similar to T3-4N2 than to T3N1. The AJCC Hindgut Taskforce sought population-based validation that depth of invasion and nodal status interact to affect survival. Patients and Methods Surveillance, Epidemiology, and End Results (SEER) population-based data from January 1992 to December 2004 for 109,953 colon cancer patients were compared with National Cancer Data Base (NCDB) data on 134,206 patients. T4N0 cancers were stratified by tumors that perforate visceral peritoneum (T4a) versus tumors that invade or are adherent to adjacent organs or structures (T4b). N1 and N2 were stratified by number of involved positive lymph nodes (N+): N1a/N1b (1 v 2-3), N2a/N2b (4 to 6 v ≥ 7). Five-year observed and relative survival data were obtained for each TN category. Results SEER colon cancer analyses confirm that patients with T1-2N0 cancers have better survival than T3N0, T3N0 better than T4N0, T1-2N2 better than T3-4N2, and T4bN1 similar to T4N2. Patients with T4a lesions have better survival than T4b by N category. The number of positive nodes affects survival for each T category. Conclusion This SEER population-based colon cancer analysis is highly consistent with rectal cancer pooled analysis and SEER rectal cancer analyses, supporting the shift of T1-2N2 lesions from IIIC to IIIA/IIIB, shifting T4bN1 from IIIB to IIIC, subdividing T4/N1/N2, and revising substaging of stages II/III. Survival outcomes by TN category for colon and rectal cancer are strikingly similar.
Percutaneous Nephrolithotomy for Large or Multiple Upper Tract Calculi and Autosomal Dominant Polycystic Kidney Disease
Umbreit, Eric , Childs, M. Adam, Patterson, David E., Torres, Vicente E. , LeRoy, Andrew J., Gettman, Matthew T., Torres, Vicente E

Mayo Clinic

Journal of Urology | November 14, 2009 | Volume: 183 | Issue: 1 | Pages: 183-187

10.1016/j.juro.2009.08.141 | PMID 19913818 Get It

Characterization of the PcCdc42 small G protein from Pneumocystis carinii, which interacts with the PcSte20 life cycle regulatory kinase
Krajicek, Bryan J. , Villegas, Leah R., Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | November 14, 2009 | Volume: 298 | Issue: 2 | Pages: L252-L260

10.1152/ajplung.00191.2009 | PMID 19915161 Get It

Pneumocystis carinii (Pc) causes severe pneumonia in immunocompromised hosts. The binding of Pc trophic forms to alveolar epithelial cells is a central feature of infection, inducing the expression and activation of PcSte20, a gene participating in mating, proliferation, and pseudohyphal growth. In related fungi, Ste20 proteins are generally activated by immediate upstream small G proteins of the Cdc42-like family. PcCdc42 has not been previously described in Pneumocystis . To address the potential role of such a G protein in Pneumocystis , PcCdc42 was cloned from a Pc cDNA library. Using the full-length 576-bp PcCdc42 cDNA sequence, a CHEF blot of genomic DNA yielded a single band, providing evidence that this gene is present as a single copy within the genome. The total length of PcCdc42 cDNA was 576 bp with an estimated molecular mass of ∼38 kDa. BLASTP analysis demonstrated greater than 80% homology with other fungal Cdc42p proteins. Northern analysis indicated equal mRNA expression in both cystic and trophic life forms. Heterologous expression of PcCdc42 in Saccharomyces cerevisiae (Sc) demonstrated that PcCdc42p was able to restore growth in an ScCdc42Δ yeast strain. Additional assays with purified PcCdc42 protein demonstrated GTP binding and intrinsic GTPase activity, which was partially but significantly suppressed by Clostridium difficile toxin B, characteristic of Cdc42 GTPases. Furthermore, PcCdc42 protein was also shown to bind to the downstream PCSte20 kinase partner in the presence (but not the absence) of GTP. These data indicate that Pc possesses a Cdc42 gene expressing an active G protein, which binds the downstream regulatory kinase PcSte20, important in Pc life cycle regulation.
Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Rodents and Nonhuman Primates
Jenks, Nathan, Myers, Rae, Greiner, Suzanne , Thompson, Jill , Mader, Emily K., Greenslade, Andrew, Griesmann, Guy E., Federspiel, Mark J. , Rakela, Jorge , Vile, Richard G. , Barber, Glen N. , Meier, Thomas R., Blanco, Michael C., Carlson, Stephanie K., Russell, Stephen J. , Peng, Kah-Whye , Jenks, Nathan J., Borad, Mitesh J. , Russell, Stephen J

Mayo Clinic

Human Gene Therapy | November 13, 2009 | Volume: 21 | Issue: 4 | Pages: 451-462

10.1089/hum.2009.111 | PMID 19911974 Get It

Spontaneous “Cardiomegaly” Following Pericardiectomy
Geske, Jeffrey B. , Calvin, Andrew D. , Geske, Jeffrey B , Calvin, Andrew D

Mayo Clinic

Journal of Cardiac Surgery | November 5, 2009 | Volume: 24 | Issue: 6 | Pages: 695-696

10.1111/j.1540-8191.2009.00852.x | PMID 20078716 Get It

Ancrod in Acute Ischemic Stroke
Zoppo, Gregory J. del, Diener, Hans‐Christoph, Howard, George , Kaste, Markku , Pancioli, Arthur , Ringelstein, E. Bernd, Spatareanu, Carmen, Wasiewski, Warren W., Levy, David E. , Demaerschalk, Bart M. , Demchuk, Andrew M. , Howard, George

Mayo Clinic

Stroke | October 30, 2009 | Volume: 40 | Issue: 12 | Pages: 3796-3803

10.1161/strokeaha.109.565119 | PMID 19875736 Get It

Background and Purpose— Previous studies of multiple-day dosing with the defibrinogenating agent, ancrod, in acute ischemic stroke yielded conflicting results but suggested that a brief dosing regimen might improve efficacy and safety. The Ancrod Stroke Program was designed to test this concept in subjects beginning ancrod or placebo within 6 hours of the onset of acute ischemic stroke. Methods— Five hundred subjects with acute ischemic stroke who could begin receiving study material within 6 hours of symptom onset were infused intravenously with either ancrod (0.167 IU/kg per hour) or placebo over 2 or 3 hours. The primary efficacy outcome was a dichotomized, modified Rankin score at 90 days with less stringent cut-points for higher prestroke modified Rankin score and pretreatment NIHSS total score (“responder analysis”). Safety variables included mortality, major bleeding, and intracranial hemorrhage. Results— Although the desired changes in fibrinogen level were seen in >90% of ancrod subjects, interim analysis for futility led to the study being halted for lack of efficacy. Positive responder status in the interim dataset was seen in 39.6% of ancrod subjects and 37.2% of placebo subjects ( P =0.47). Ninety-day mortality did not differ between the 2 groups (ancrod, 15.6%; placebo, 14.1%; P =0.32), and the incidence of symptomatic intracranial hemorrhage within the first 72 hours, although not significantly different in ancrod compared to placebo subjects ( P =0.19), was approximately twice as high (3.9% vs 2.0%; P =0.19). Conclusion— These results demonstrate that intravenous ancrod starting within 6 hours after symptom onset in a broad selection of subjects with ischemic stroke did not improve their outcome and revealed a trend to increased bleeding despite successful efforts to achieve rapid initial defibrinogenation and avoid prolonged hypofibrinogenemia.
Nicotine response genetics in the zebrafish
Petzold, Andrew M. , Balciunas, Darius , Sivasubbu, Sridhar , Clark, Karl J. , Bedell, Victoria M. , Westcot, Stephanie, Myers, Shelly R., Moulder, Gary, Thomas, Mark J. , Ekker, Stephen C. , Ekker, Stephen C , Clark, Karl J , Balciunas, Darius

Mayo Clinic

Proceedings of the National Academy of Sciences | October 26, 2009 | Volume: 106 | Issue: 44 | Pages: 18662-18667

10.1073/pnas.0908247106 | PMID 19858493 Get It

Tobacco use is predicted to result in over 1 billion deaths worldwide by the end of the 21 st century. How genetic variation contributes to the observed differential predisposition in the human population to drug dependence is unknown. The zebrafish ( Danio rerio ) is an emerging vertebrate model system for understanding the genetics of behavior. We developed a nicotine behavioral assay in zebrafish and applied it in a forward genetic screen using gene-breaking transposon mutagenesis. We used this method to molecularly characterize bdav /cct8 and hbog /gabbr1.2 as mutations with altered nicotine response. Each have a single human ortholog, identifying two points for potential scientific, diagnostic, and drug development for nicotine biology and cessation therapeutics. We show this insertional method generates mutant alleles that are reversible through Cre-mediated recombination, representing a conditional mutation system for the zebrafish. The combination of this reporter-tagged insertional mutagen approach and zebrafish provides a powerful platform for a rich array of questions amenable to genetic-based scientific inquiry, including the basis of behavior, epigenetics, plasticity, stress, memory, and learning.
A 74-year-old woman with progressive right-hand tremor and inability to use her right side
Kertesz, Andrew , Fealey, Robert D., Parisi, Joseph E. , Keegan, B. Mark

Mayo Clinic

Neurology | October 26, 2009 | Volume: 73 | Issue: 17 | Pages: 1399-1405

10.1212/wnl.0b013e3181bd80fe | PMID 19858463 Get It

Dose to Radiosensitive Organs During Routine Chest CT: Effects of Tube Current Modulation
Angel, Erin , Yaghmai, Nazanin, Jude, Cecilia M., DeMarco, John J., Cagnon, Christopher H., Goldin, Jonathan , Primak, Andrew N. , Cody, Dianna D. , Stevens, Donna M., Cagnon, Chris H., McCollough, Cynthia H. , McNitt‐Gray, Michael F.

Mayo Clinic

American Journal of Roentgenology | October 20, 2009 | Volume: 193 | Issue: 5 | Pages: 1340-1345

10.2214/ajr.09.2886 | PMID 19843751 Get It

The efficacy and safety of enhanced external counterpulsation in patients with peripheral arterial disease
Thakkar, Bhavik V, Hirsch, Alan T., Satran, Daniel, Bart, Bradley A. , Barsness, Gregory W. , Kennard, Elizabeth D., Kelsey, Sheryl F., Henry, Timothy D. , McCullough, Peter Andrew

Mayo Clinic

Vascular Medicine | October 20, 2009 | Volume: 15 | Issue: 1 | Pages: 15-20

10.1177/1358863x09106549 | PMID 19841026 Get It

Peripheral arterial disease (PAD) is common in patients with severe coronary artery disease (CAD) and is considered a relative contraindication to external enhanced counterpulsation (EECP), but there are no data that define the efficacy and safety of EECP in patients with PAD. The International EECP Patient Registry (IEPR) was used to compare initial post-therapy and 2-year follow-up clinical outcomes and adverse event rates in patients with and without PAD. From January 2002 to October 2004, 2126 patients were enrolled in the IEPR, of whom 493 (23%) had a history of PAD. Immediately following EECP, the reduction in angina (≥ 1 Canadian Cardiovascular Society class) was similar in patients with and without PAD (76.6% vs 79.0%, p = 0.27) as was improvement in the Duke Activity Score Index (DASI) score (+4.7% vs +6.1%, p < 0.001). Both angina reduction and DASI score improvement were sustained at 2 years. PAD patients discontinued EECP more frequently (12.0% vs 8.5%, p < 0.05), but lower extremity ulceration did not occur more frequently in patients with PAD (3.7% vs 2.7%, p = 0.26). Rates of death (17.1% vs 8.6%, p < 0.001) and myocardial infarction (9.5% vs 5.0%, p < 0.001) were, as expected, higher in patients with PAD compared to patients without PAD at 2 years. In conclusion, while PAD patients constitute a high-risk cohort with known higher adverse event rates, EECP led to similar short- and long-term improvements in angina and quality of life for individuals with PAD compared to those without PAD.